.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 3,852,446

« Back to Dashboard

Details for Patent: 3,852,446

Title: ORGANIC COMPOUNDS IN TREATMENT OF PSYCHOTIC DISTURBANCES
Abstract:This invention concerns the use of the compound 2-nitro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]-thiazepine, as a neuroleptic agent.
Inventor(s): Schmutz; Jean (Muri Near Berne, CH), Hunziker; Fritz (Berne, CH)
Assignee: Sandoz, Inc. (Hanover, NJ)
Filing Date:Mar 19, 1973
Application Number:05/342,399
Claims:1. A pharmaceutical composition in the form of a tablet, capsule or dragee useful in treating psychotic disturbances in animals comprising as active ingredient, a therapeutically effective amount of 2-nitro-11-(4-methyl-1-piperazinyl)dibenzo[b,f] [1,4]thiazepine, or a pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutical carrier or diluent.

2. A pharmaceutical composition in the form of a tablet, capsule or dragee useful in treating psychotic disturbances in animals according to claim 1, wherein the active ingredient is present in said composition in an amount sufficient to provide a daily dosage of from about 1 milligram to about 50 milligrams of the active ingredient.

3. A pharmaceutical composition in the form of a tablet, capsule or dragee useful in treating psychotic disturbances in animals according to claim 2, in unit dosage form, wherein the amount of active ingredient is from about 0.25 milligrams to about 25 milligrams.

4. A method of treating psychotic disturbances in animals, which comprises administering to an animal in need of said treatment a therapeutically effective amount of 2-nitro-11-(4-methyl-1-piperazinyl)-dibenzo[b,f] [1,4]thiazepine, or a pharmaceutically acceptable acid addition salt thereof.

5. A method according to claim 4, which comprises administering to the animal a daily dosage of from about 0.01 to about 2 mg per kilogram animal body weight of 2-nitro-11-(4-methyl-1-piperazinyl)-dibenzo[b,f] [1,4]thiazepine, or a pharmaceutically acceptable acid addition salt thereof.

6. A method according to claim 5, which comprises administering to the animal a daily dosage of from about 1 mg to about 50 mg of 2 nitro-11-(4-methyl-1-piperazinyl)dibenzo[b,f] [1,4]thiazepine, or a pharmaceutically acceptable acid addition salt thereof.

7. A method according to claim 6, wherein the daily dosage is given in divided doses 2 to 4 times a day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc